Your drug can't be branded until it's approved, but your competitors are already educating the specialists who will prescribe it. We build the unbranded, disease-state demand engine that has your audience warmed up and waiting the day you get the green light.
The Problem
Marketing goes dark for 18 to 36 months
Most biotech marketing teams treat the pre-approval window as dead time because they can't make a single product claim. So they wait. By the time FDA clears the drug, the HCPs who will prescribe it have never heard the company name, never engaged with a piece of content, never opened an email. Launch day starts from zero instead of from a warm list.
Budget dumps all at once instead of building over time
Demand gen dollars sit parked until the day of approval, then get dropped into paid media in one lump sum. That buys impressions, not trust – a specialist who sees your branded ad for the first time on launch day has no context for why they should care. Money spent building disease-state awareness two years earlier would have converted at a fraction of the cost.
Medical affairs and commercial run on separate clocks
MSLs are already having disease-state conversations with key opinion leaders well before approval, feeding scientific exchange with no marketing counterpart. Commercial teams aren't capturing any of that ground game because there's no unbranded content or audience infrastructure to plug it into. The two functions end up building separate, disconnected relationships with the same doctors.
Agencies default to the mass-market DTC playbook
Most pharma marketing shops are built for consumer campaigns – broad reach, brand claims, big budgets. Unbranded HCP demand gen is the opposite: a target list of a few thousand named specialists, a message that can't mention the product, and a buying cycle measured in prescribing behavior, not clicks. Agencies built for DTC scale don't know how to run this, so they either skip it or run it like a consumer campaign and waste the budget.
How We Help
We start by mapping where your disease state already has a presence and where it doesn't. That means pulling together what medical affairs has learned from KOL conversations, what your regulatory timeline actually allows you to say today versus in six months, and who the real target list is – by specialty, by prescribing volume, by geography. Most biotech teams have this information scattered across three departments that don't talk to each other. We put it in one place and use it to build the plan.
From there we build the unbranded content and channel strategy tied to your specific regulatory milestones, not a generic launch calendar. If you're 24 months from approval, the plan looks different than if you're 6 months out. Early phase is pure disease education – epidemiology, patient burden, unmet need. As you get closer to approval, content shifts toward mechanism-of-action-adjacent education that stays inside regulatory lines while building the case your sales team will make later.
We build the disease-state content engine: articles, webinars, and HCP-facing digital assets that establish your team as a source on the condition, not the product. This gets distributed through specialty publisher networks, programmatic display targeted by NPI data, and paid social aimed at the specific prescriber segments who matter. None of it mentions your drug. All of it puts your name in front of the right doctor before they know why it matters.
In parallel we build the audience infrastructure – the NPI-matched contact and engagement database that tracks which specialists opened what, attended what, downloaded what. This becomes the warm list your commercial team inherits on launch day, instead of starting from a purchased list with zero context.
We track engagement against regulatory milestones instead of vanity impressions – who's returning to your content, who's escalating from awareness assets to deeper clinical material, which specialty segments are showing signal. Every 90 days we report what's working, kill what isn't, and adjust the plan as your approval timeline moves, because it will move.
As approval nears, we build the branded transition plan with your commercial and legal teams – what content converts from unbranded to branded, which audience segments get the warm handoff first, and how the message shifts from disease education to product without losing the trust you spent two years building.
What we deliver
- Disease-state content engine – unbranded, HCP-facing education content (articles, webinars, clinical-adjacent assets) mapped to your regulatory timeline, never mentioning the product.
- NPI-matched audience build – a prescriber database segmented by specialty and engagement level, tracked from first touch through launch handoff.
- Pre-launch nurture program – email, webinar, and content sequencing timed to regulatory milestones, keeping specialists engaged across the multi-year runway to approval.
- Launch-readiness handoff plan – the branded transition strategy, built with legal and commercial, that converts your unbranded audience into a launch-day sales asset.
The specialists who will prescribe your drug are being educated by somebody right now – the only question is whether it's you or a competitor who started earlier.
Our Methodology
We run this like every other Winston Francois engagement: in 90-day sprints, not a two-year plan you set once and hope holds. Pre-launch demand gen has a runway of 18 months, 24 months, sometimes longer, but nobody can predict FDA timelines with certainty, so we don't plan like they can. Each sprint has a fixed set of deliverables, a review, and a decision point on what changes for the next 90 days based on what the data and the regulatory calendar are telling us.
Sprint one is always assessment and infrastructure – audience list, content foundation, channel setup. From sprint two on, it's content production, distribution, and measurement on a repeating cycle, with the content mix shifting as you move closer to approval. If your timeline slips six months, the sprint structure absorbs it without blowing up the whole plan.
This works because it treats pre-launch demand gen as an operating function, not a campaign with a start and end date. You get a team that ships every 90 days, reports what moved, and stays flexible enough to handle a regulatory calendar that never behaves.
How We Work
First 30 days: we audit your current disease-state footprint (or lack of one), pull together the regulatory timeline with your legal team, and build the NPI-matched target list with your medical affairs and commercial leads. You get a demand gen plan mapped to your actual approval timeline, not a generic template.
Days 30 to 60: content production starts. We build the first wave of unbranded, disease-state assets and stand up the distribution channels – specialty publisher placements, NPI-targeted programmatic, paid social to the right prescriber segments. This is also when the engagement tracking infrastructure goes live so every touch gets attributed to a named specialist.
Days 60 to 90: the first content wave is live and generating engagement data. We report what's resonating by specialty and channel, kill what isn't, and lock the content calendar for the next sprint. By day 90 you have a working demand gen engine, not a strategy deck.
You get a small dedicated team – a strategist who owns the plan, a content lead who owns production, and a paid media specialist who owns distribution – working direct with your CMO or VP Marketing, plus a standing touchpoint with medical affairs so the unbranded work stays aligned with what MSLs are hearing in the field. Weekly check-ins, a written report every 90 days, no account layer between you and the people doing the work.
- A warmed, NPI-matched prescriber audience handed to commercial on launch day instead of a cold list.
- A reusable disease-state content library that carries value across the full launch lifecycle, not a one-off campaign.
- Engagement data tied to named specialists and tracked against your regulatory timeline, so you know what's working before you're allowed to say a word about the product.
If your biotech & pharma company needs demand generation leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does biotech and pharma demand gen with Winston Francois cost?
Most pre-launch demand gen engagements run $15,000 to $35,000 per month, depending on how many specialty segments you're targeting and how much content production the plan calls for. Paid media spend for programmatic and publisher placements is separate and scales with your target list size. We price the engagement to your regulatory timeline, not a fixed retainer menu.
How early before FDA approval should we start unbranded demand gen?
18 to 24 months out is the sweet spot for most Phase 3 assets, though we've started as early as Phase 2 readout for competitive indications. The honest answer is earlier than you think, because disease-state education takes time to build trust with specialists, and your competitors targeting the same indication are probably already running theirs. Starting at launch is starting from zero.
How does your team work with our existing medical affairs and MSL team?
We build a standing touchpoint into every sprint so the unbranded demand gen content stays consistent with what your MSLs are hearing from KOLs in the field. We're not trying to own medical affairs' relationships – we're building the marketing infrastructure that supports what they're already doing, so commercial isn't starting a separate conversation with the same doctors.
How is this different from hiring a pharma marketing agency?
Most pharma agencies are built for branded, mass-market DTC campaigns – big budgets, broad reach, product claims. Unbranded HCP demand gen needs the opposite: tight targeting on a few thousand named specialists, message discipline that stays inside regulatory lines, and patience for a multi-year runway. We run this as a fractional team embedded with your CMO, not an agency account team billing hours against a media plan.
How do you measure ROI before the product is even approved?
We track engagement signal tied to named specialists – who's returning to your content, who's escalating from awareness-level material to deeper clinical assets, which specialty segments show the strongest response. That data tells you which parts of your target audience are primed for the branded conversion at launch, which is the real ROI question before approval: are we building an audience that converts, not are we selling units we can't sell yet.
What kind of biotech or pharma company is the best fit for this?
Companies with an asset in Phase 2 or later, a defined indication, and a commercial launch inside the next one to three years. If you're pre-clinical, it's too early – there's no defined indication to educate on yet. If you're already approved and branded, this isn't the engagement; that's a different kind of demand gen work.
